Hepatitis C and its impact on renal transplantation

Nature Reviews Nephrology

Volumn 11, Issue 3, 2015, Pages 172-182

  Morales, Jose M ^a   Fabrizi, Fabrizio ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DACLATASVIR; INTERFERON; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS ANTIBODY; VIRUS PROTEIN;

ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; ARTICLE; DIABETES MELLITUS; GLOMERULOPATHY; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER DISEASE; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; SECONDARY INFECTION; SURVIVAL; TREATMENT DURATION; VIRUS LOAD; VIRUS RESISTANCE; HEPATITIS C, CHRONIC; MORTALITY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE;

GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE;

EID: 84923779309     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.5     Document Type: Article

References (118)

1. Pereira, B. J. & Levey, A. S. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 51, 981-999 (1997).
2. Roth, D. Hepatitis C virus: the nephrologist's view. Am. J. Kidney Dis. 25, 3-16 (1995).
3. Morales, J. M. & Dominguez-Gil, B. Transplantation in the patient with hepatitis C. Transplant. Int. 22, 1117-1131 (2009).
4. EBPG (European Expert Group on Renal Transplantation), European Renal Association (ERA-EDTA) & European Society for Organ Transplantation (ESOT). European Best Practice Guidelines for Renal Transplantation (Part 1). Section I: Evaluation, selection and preparation of the potential recipient. Nephrol. Dial. Transplant. 15 (Suppl. 7), 3-38 (2000).
5. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int. 73 (Suppl. 109), S1-S99 (2008).
6. Fabrizi, F., Messa, P. & Martin, P. Update to hepatitis C review. Kidney Int. 85, 1236-1239 (2014).
7. Terrault, N. S. & Stock, P. G. Management of hepatitis C in kidney transplant patients: on the cusp of change. Am. J. Transplant. 14, 1995-1957 (2014).
8. Lens, S., Gambato, M., Londono, M. C. & Forns, X. Interferon-free regimens in the livertransplant setting. Semin. Liver Dis. 34, 58-71 (2014).
9. Covic, A. et al. Hepatitis C virus infection in haemodialysis patients from Moldavia. Nephrol. Dial. Transplant. 14, 40-45 (1999).
10. Jadoul, M. et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol. Dial. Transplant. 19, 904-909 (2004).
11. Morales, J. M. et al. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol. Dial. Transplant. 19 (Suppl. 3), 72-76 (2004).
12. Kliem, V. et al. Relationship of hepatitis B or C prevalence, risk factors and outcomes in renal transplant recipients. Analysis of German data. Transplant. Proc. 40, 909-914 (2008).
13. Scott, D. R. et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 90, 1165-1171 (2010).
14. Gentil Govantes, M. A. et al. Harmful effects of viral replication in seropositive hepatitis C virus renal transplant recipients. Transplantation 94, 1131-1137 (2012).
15. Vosnides, G. G. Hepatitis C in renal transplantation. Nephrology Forum. Kidney Int. 52, 843-861 (1997).
16. Watashi, K. et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282-1288 (2003).
17. Roth, D. et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 61, 886-889 (1996).
18. El-Sherif, A. et al. High false-negative rate of anti-HCV among Egyptian patients on regular haemodialysis. Haemodial. Int. 16, 420-427 (2012).
19. Baid-Agrawal, S. et al. Prevalence of occult hepatitis C infection in chronic haemodialysis and kidney transplant patients. J. Hepatol. 60, 928-933 (2014).
20. Tillmann, H. L. Hepatitis C core antigen testing: role in diagnosis, disease monitoring and treatment. World J. Gastroenterol. 20, 701-706, 706 (2014).
21. Muñoz de Bustillo, E. et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant patients. J. Am. Soc. Nephrol. 9, 1109-113 (1998).
22. Luan, F. L. et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 85, 1601-1606 (2008).
23. Cortijo, C. Impacto de la terapia de induccion con agents biologicos en los resultados del trasplante renal en pacientes con infeccion por le virus de la hepatitis C [Spanish]. Thesis, Universidad Europea de Madrid, Spain (2012).
24. Kucirka, L. M., Peters, T. G. & Segev, D. L. Impact of donor hepatitis C virus infection on death and need for liver transplant in hepatitis C viruspositive kidney transplant recipients. Am. J. Kidney Dis. 60, 112-120 (2012).
25. Glicklich, D. et al. Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Am. J. Gastroenterol. 94, 159-163 (1999).
26. Zylberberg, H. et al. Severe evolution of chronic hepatitis C in renal transplantation. A case control study. Nephrol. Dial. Transplant. 17, 129-133 (2002).
27. Izopet, J. et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J. Infect. Dis. 181, 852-858 (2000).
28. Alric, L. et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 123, 1494-1499 (2002).
29. Kamar, N. et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am. J. Transplant. 5, 1704-1712 (2005).
30. Roth, D. et al. Clinical outcomes in hepatitis C patients before and after kidney transplantation. J. Am. Soc. Nephrol. 22, 1152-1160 (2011).
31. Toz, H. et al. The acquisition time of infection: a determinant of the severity of hepatitis C virusrelated liver disease in renal transplant patients. Clin. Transplant. 23, 723-731 (2009).
32. Alric, L. et al. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic hepatitis. Transplant. Int. 22, 568-573 (2009).
33. Roth, D. & Bloom, R. Selection and management of hepatitis C virus-infected patients for the kidney transplant waiting list. Contrib. Nephrol. 176, 66-76 (2012).
34. Eason, J. D. et al. Proceedings of consensus conference on simultaneous liver kidney transplantation. Am. J. Transplant. 8, 2243-2251 (2008).
35. Fabrizi, F., Aghemo, A. & Messa, P. Hepatitis C treatment in patients with kidney disease. Kidney Int. 84, 874-879 (2013).
36. Pageaux, G. et al. Pegylated interferon-alpha based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transplant. Int. 22, 562-567 (2009).
37. Fabrizi, F., Dixit, V., Messa, P. & Martin, P. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. J. Viral. Hepatol. 21, 681-689 (2014).
38. Gordon, C. E. et al. Interferon treatment in haemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am. J. Kidney Dis. 51, 263-277 (2008).
39. Gordon, C. E. et al. Long-term viral negativity after interferon for chronic hepatitis C virus infection in haemodialysis. Clin. J. Am. Soc. Nephrol. 8, 2226-2234 (2011).
40. Goodkin, D. A. et al. Hepatitis C infection is very rarely treated among haemodialysis patients. Am. J. Nephrol. 38, 405-12 (2013).
41. Fabrizi, F. et al. Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies. J. Med. Virol. 86, 933-940 (2014).
42. Fabrizi, F. et al. Meta-analysis: antiviral therapy of hepatitis C virus-related liver disease in renal transplant recipients. Aliment. Pharmacol. Ther. 24, 1413-1422 (2006).
43. Schmitz, V. et al. Peginterferon innodataalpha-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann. Transplant. 12, 22-27 (2007).
44. Van Vagner, L. et al. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J. Hepatol. 51, 874-880 (2009).
45. Hassan, Q. et al. Liver-kidney recipients with chronic viral hepatitis C treated with interferonalpha. Transplant. Int. 25, 91-94 (2012).
46. Alijumah, A. et al. Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. World J. Gastroenterol. 18, 55-63 (2012).
47. Sanai, F. et al. Safety and efficacy of peginterferon-innodataalpha 2b plus ribavirin treatment in renal transplant recipients with chronic hepatitis C. J. Hepatol. 58, 1096-1103 (2013).
48. Kramer, P. et al. Recombinant leucocyte interferon-A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1, 989-990 (1984).
49. Kovarik, J. et al. Adverse effect of low-dose prophylactic human recombinant leucocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increase incidence of irreversible rejections. Transplantation 45, 402-405 (1988).
50. Aghemo, A. & De Francesco, R. New horizons in hepatitis C antiviral therapies with direct-acting antivirals. Hepatology 58, 428-438 (2013).
51. Yau, A. & Yoshida, E. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can. J. Gastroenterol. Hepatol. 28, 445-451 (2014).
52. Pawlotsky, J. M. New hepatitis C virus drugs and the hope for a cure: concepts in anti-HCV drug development. Semin. Liver Dis. 34, 22-29 (2014).
53. Pol, S. & Corouge, M. Treatment of hepatitis C: perspectives. Med. Mal. Infect. 44, 449-454 (2014).
54. Dumortier, J. et al. Antiviral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J. Clin. Virol. 56, 146-149 (2013).
55. Delabaudiere, C. et al. Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined-liver transplantation. Transplant. Int. http://dx.doi.org/10.111/tri.12428.
56. FDA. FDA approves first combination pill to treat hepatitis C. www.fda.gov [online], http:// www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm418365.htm.
57. Corell, A. et al. Immunosuppression induced by hepatitis C virus infection reduces acute renal transplant rejection. Lancet 346, 1497-1498 (1995).
58. Forman, J. P. et al. Hepatitis C, acute humoral rejection, and renal allograft survival. J. Am. Soc. Nephrol. 15, 249-255 (2004).
59. Morales, J. M. et al. Renal transplantation in patients with hepatitis C virus antibody. A long national experience. NDT Plus 3 (Suppl. 2), ii41-ii46 (2010).
60. Mitwalli, A. H. et al. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin. Pract. 102, c72-c80 (2006).
61. Morales, J. M. et al. Long-term experience with kidney transplantation from hepatitis C positive donors into hepatitis C positive recipients. Am. J. Transplant. 10, 2453-2462 (2010).
62. Lopez Medrano, F. et al. Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation. Data from the RESITRA/REIPI cohort. Transplantation 92, 543-549 (2011).
63. Torres, J. et al. Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation. Transplant. Int. 21, 873-878 (2008).
64. Manuel, O. et al. Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. Contrib. Nephrol. 176, 97-107 (2012).
65. Burra, P. et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur. J. Gastroenterol. Hepatol. 18, 1065-1070 (2006).
66. Caillard, S. et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am. J. Transplant. 6, 2735-2742 (2006).
67. Caillard, S. et al. Myeloma, Hodgkin disease and lymphoid leukaemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 27, 888-895 (2006).
68. Kondo, Y. & Shimosegawa, T. Direct effect of hepatitis C virus on the lymphoid cells. World J. Gastroenterol. 19, 7889-7895 (2013).
69. Takahashi, K. et al. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern. Med. 51, 2745-2747 (2012).
70. Fabrizi, F. et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation. Meta-analysis of clinical studies. Am. J. Transplant. 5, 2433-2440 (2005).
71. Cruzado, J. M., Bestard, O. & Grinyo, J. M. Impact of extrahepatic complications (diabetes and glomerulonephritis) associated with hepatitis C virus infection after renal transplantation. Contrib. Nephrol. 176, 108-116 (2012).
72. Bloom, R. D. et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J. Am. Soc. Nephrol. 13, 1374-1380 (2002).
73. Kasiske, B. L. et al. Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. 3, 175-185 (2003).
74. Morales J. M. et al. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr. Opin. Nephrol. Hypertens. 6, 511-515 (1997).
75. Perico, N. et al. Hepatitis C infection and chronic renal diseases. Clin. Am. Soc. Nephrol. 4, 207-220 (2009).
76. Fabrizi, F. et al. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin. J. Am. Soc. Nephrol. 7, 549-557 (2012).
77. Cruzado, J. M. et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J. Am. Soc. Nephrol. 7, 2469-2475 (1996).
78. Morales, J. M. et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 63, 1634-1639 (1997).
79. Baid-Agrawal, S. et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allografts recipients. J. Am. Soc. Nephrol. 10, 146-153 (1999).
80. Baid-Agrawal, S. et al. Hepatitis C virus infection and kidney transplantation in 2014. What's new? Am. J. Transplant. 14, 2206-2220 (2014).
81. Hestin, D. et al. Pre-transplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation 65, 741-744 (1998).
82. Wornle, M. et al. Novel role of toll-like receptor 3 in hepatitis C-assciated glomerulonephritis. Am. J. Pathol. 168, 370-385 (2006).
83. Castillo, I. et al. High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropaties. Kidney Int. 86, 619-624 (2014).
84. Fabrizi, F., Messa, P. & Martin, P. Novel evidence on hepatitis C virus-associated glomerular disease. Kidney Int. 86, 466-469 (2014).
85. Cosio, F. G. et al. Prevalence of hepatitis C virus in patients with idiopathic glomerulopathies in native and transplanted kidneys. Am. J. Kidney Dis. 28, 752-758 (1996).
86. Baid-Agrawal, S. et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int. 80, 879-885 (2011).
87. Legendre, C. et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65, 667-670 (1998).
88. Mathurin, P. et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29, 257-263 (1999).
89. Maluf, D. G. et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 83, 853-857 (2007).
90. Bruchfeld, A., Wilczek, H. & Einder, C. G. Hepatitis C infection, time in renal-replacement therapy and outcome after kidney transplantation. Transplantation 78, 745-750 (2004).
91. Gentil, M. A. et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol. Dial. Transplant. 94, 2455-2460 (1999).
92. Fabrizi, F. et al. Hepatitis C virus antibody status and survival after renal transplantation: metaanalysis of observational studies. Am. J. Transplant. 5, 1452-1461 (2005).
93. Rostami, Z. et al. The impact of hepatitis C virus infection on kidney transplantation outcomes: a systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepat. Mon. 11, 247-254 (2011).
94. Adinolfi, L. et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J. Gastroenterol. 20, 3410-3417 (2014).
95. Fabrizi, F. et al. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J. Viral Hepat. 21, 314-324 (2014).
96. Knoll, G. A. et al. The impact of renal transplantation on survival in hepatitis C positive end-stage renal disease patients. Am. J. Kidney Dis. 29, 606-614 (1997).
97. Pereira, B. J. et al. Effects of hepatitis C infection and renal transplantation on survival in endstage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 53, 1374-1381 (1998).
98. Bloom, R. D. et al. Outcome of hepatitis C virusinfected kidney transplant candidates who remain on the waiting list. Am. J. Transplant. 5, 139-144 (2005).
99. Ingsathit, A. et al. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and metaanalysis. Transplantation 95, 943-948 (2013).
100. Wolfe, R. A. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. N. Engl. J. Med. 341, 1725-1730 (1999).
101. Martin, E. F. et al. Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation. An analysis of the United Network for Organ Sharing database. Liver Transplant. 18, 914-929 (2012).
102. Xia, Y. et al. Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am. J. Transplant. 14, 2037-2047 (2014).
103. Mahmoud, I. M. et al. The impact of hepatitis C virus viraemia on renal graft and patient survival: a 9-year prospective study. Am. J. Kidney Dis. 43, 131-139 (2004).
104. Abbott, K. C. et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J. Am. Soc. Nephrol. 14, 2908-2918 (2003).
105. Lin, H. H. et al. Impact of HCV infection on first cadaveric renal transplantation: a single centre experience. Clin. Transplant. 18, 261-266 (2004).
106. Pereira, B. J. et al. Transmission of hepatitis C virus by organ transplantation. N. Engl. J. Med. 325, 454-460 (1991).
107. Morales, J. M., Andres, A. & Campistol J. M. Hepatitis C virus and renal transplantation. N. Engl. J. Med. 328, 511-512 (1993).
108. Morales, J. M. et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int. 47, 236-240 (1995).
109. Bucci, J. R. et al. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin. Transpl. 2004, 51-61 (2004).
110. Bucci, J. R. et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J. Am. Soc. Nephrol. 13, 2974-2982 (2002).
111. Abbott, K. C. et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am. J. Transplant. 4, 2032-2037 (2004).
112. Maluf, D. G., Archer, K. J. & Mas, V. R. Kidney grafts from HCV-positive donors: advantages and disadvantages. Transplant. Proc. 42, 2436-2446 (2010).
113. Singh, N. et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin. Transplant. 26, 684-693 (2012).
114. Ali, M. K. et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation 66, 1694-1697 (1998).
115. Mandal, A. K. et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin. Transplant. 14, 391-396 (2000).
116. Widell, A. et al. Hepatitis C superinfection in hepatitis C virus (HCV) infected patients transplanted with an HCV infected kidney. Transplantation 60, 642-647 (1995).
117. Dominguez-Gil, B. et al. Should we be using kidneys from hepatitis C virus-infected donors? Curr. Opin. Nephrol. Hypertens. 20, 599-604 (2011).
118. Kucirka, L. M. et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am. J. Transplant. 10, 1238-1246 (2010).